ANN ARBOR, Mich., March 26, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk.
“This is a major financial milestone for Kraig. For many years we have operated on a shoestring budget, building a solid foundation with our spider silk production system. We are now prepared to reap the rewards of that careful investment with opportunities to put this capital to work building materials, products and brands,” said CEO and Founder, Kim Thompson.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…